Loading…
Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice
The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus)...
Saved in:
Published in: | Nutrition and cancer 2021, Vol.73 (10), p.2089-2099 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683 |
---|---|
cites | cdi_FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683 |
container_end_page | 2099 |
container_issue | 10 |
container_start_page | 2089 |
container_title | Nutrition and cancer |
container_volume | 73 |
creator | Rahimi, Ahmad Mustafa Nabavizadeh, Fatemeh Ashabi, Ghorbangol Halimi, Shahnaz Rahimpour, Milad Vahedian, Jalal Panahi, Mahshid |
description | The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus) was compared with the capecitabine drug as known used drug against GC. Human GC tissue was obtained from patients with gastric adenocarcinoma and grafted into mice armpit. Probiotic (L. rhamnosus) was given to animals by gavage 2 weeks prior to GC and 4 weeks after GC induction. Also, capecitabine was orally added through feeding tube at the last week of treatment procedure. All grafted animals received cyclosporine a day before the surgery and during the study period to prevent graft rejection. Capecitabine-probiotic complex reduced the size of the axillary implanted GC when compared with control group. Furthermore, combination of capecitabine and probiotic increased apoptotic and necrotic responses in the grafted tumor, blood cells (red blood cells, white blood cells, and platelet counts) in comparison with capecitabine. Probiotic (L. rhamnosus) administration effectively improved the therapeutic index and outcomes, and also, improved the therapeutic effects of the capecitabine. |
doi_str_mv | 10.1080/01635581.2020.1832237 |
format | article |
fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_journals_2581653436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2581653436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683</originalsourceid><addsrcrecordid>eNp9kc9uFSEUh4mxsdfqI2hI3LiZlr8Ds7O9qdcmt9HEdk0YBizNDIzAtOkz-NJyc29duOiKE_KdH-fwAfABo1OMJDpDuKWcS3xKEKlXkhJCxSuwwpySRnSYvQarHdPsoGPwNud7hJDAVL4Bx5R2nItOrMCfHyn2PhZv4FabEntt_DguGaY7PYWYa_VzmefRTjYUXXwM8GqaU3ywA1zr2RpfdO-DhTWnWFP8g4WXztUK6l_ah1zgRueSav5aB2MT3KT4WO6gD_BajxZenG8vzgy89sa-A0dOj9m-P5wn4Pbr5c36W7P9vrlan28bQ1FXGqMlctzV8QcsHGPEYisxd1y6gVGORG84buXg2r4bhGCMDkiYjjlBHJKtpCfg8z637vF7sbmoyWdjx1EHG5esCCekxS2TuKKf_kPv45JCna5SErecMtpWiu8pk2LOyTo1Jz_p9KQwUjtb6tmW2tlSB1u17-MhfeknO_zretZTgS97wAcX06QfYxoHVfTTGJNL9T99VvTlN_4CKvSkMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2581653436</pqid></control><display><type>article</type><title>Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Rahimi, Ahmad Mustafa ; Nabavizadeh, Fatemeh ; Ashabi, Ghorbangol ; Halimi, Shahnaz ; Rahimpour, Milad ; Vahedian, Jalal ; Panahi, Mahshid</creator><creatorcontrib>Rahimi, Ahmad Mustafa ; Nabavizadeh, Fatemeh ; Ashabi, Ghorbangol ; Halimi, Shahnaz ; Rahimpour, Milad ; Vahedian, Jalal ; Panahi, Mahshid</creatorcontrib><description>The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus) was compared with the capecitabine drug as known used drug against GC. Human GC tissue was obtained from patients with gastric adenocarcinoma and grafted into mice armpit. Probiotic (L. rhamnosus) was given to animals by gavage 2 weeks prior to GC and 4 weeks after GC induction. Also, capecitabine was orally added through feeding tube at the last week of treatment procedure. All grafted animals received cyclosporine a day before the surgery and during the study period to prevent graft rejection. Capecitabine-probiotic complex reduced the size of the axillary implanted GC when compared with control group. Furthermore, combination of capecitabine and probiotic increased apoptotic and necrotic responses in the grafted tumor, blood cells (red blood cells, white blood cells, and platelet counts) in comparison with capecitabine. Probiotic (L. rhamnosus) administration effectively improved the therapeutic index and outcomes, and also, improved the therapeutic effects of the capecitabine.</description><identifier>ISSN: 0163-5581</identifier><identifier>EISSN: 1532-7914</identifier><identifier>DOI: 10.1080/01635581.2020.1832237</identifier><identifier>PMID: 33955797</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adenocarcinoma ; Animals ; Apoptosis ; Blood ; Cancer ; Carcinogenesis ; Carcinogens ; Cyclosporins ; Dietary supplements ; Erythrocytes ; Gastric cancer ; Graft rejection ; Grafting ; Lactobacilli ; Lactobacillus rhamnosus ; Leukocytes ; Probiotics ; Supplements ; Xenografts ; Xenotransplantation</subject><ispartof>Nutrition and cancer, 2021, Vol.73 (10), p.2089-2099</ispartof><rights>2020 Taylor & Francis Group, LLC 2020</rights><rights>2020 Taylor & Francis Group, LLC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683</citedby><cites>FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33955797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahimi, Ahmad Mustafa</creatorcontrib><creatorcontrib>Nabavizadeh, Fatemeh</creatorcontrib><creatorcontrib>Ashabi, Ghorbangol</creatorcontrib><creatorcontrib>Halimi, Shahnaz</creatorcontrib><creatorcontrib>Rahimpour, Milad</creatorcontrib><creatorcontrib>Vahedian, Jalal</creatorcontrib><creatorcontrib>Panahi, Mahshid</creatorcontrib><title>Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice</title><title>Nutrition and cancer</title><addtitle>Nutr Cancer</addtitle><description>The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus) was compared with the capecitabine drug as known used drug against GC. Human GC tissue was obtained from patients with gastric adenocarcinoma and grafted into mice armpit. Probiotic (L. rhamnosus) was given to animals by gavage 2 weeks prior to GC and 4 weeks after GC induction. Also, capecitabine was orally added through feeding tube at the last week of treatment procedure. All grafted animals received cyclosporine a day before the surgery and during the study period to prevent graft rejection. Capecitabine-probiotic complex reduced the size of the axillary implanted GC when compared with control group. Furthermore, combination of capecitabine and probiotic increased apoptotic and necrotic responses in the grafted tumor, blood cells (red blood cells, white blood cells, and platelet counts) in comparison with capecitabine. Probiotic (L. rhamnosus) administration effectively improved the therapeutic index and outcomes, and also, improved the therapeutic effects of the capecitabine.</description><subject>Adenocarcinoma</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Blood</subject><subject>Cancer</subject><subject>Carcinogenesis</subject><subject>Carcinogens</subject><subject>Cyclosporins</subject><subject>Dietary supplements</subject><subject>Erythrocytes</subject><subject>Gastric cancer</subject><subject>Graft rejection</subject><subject>Grafting</subject><subject>Lactobacilli</subject><subject>Lactobacillus rhamnosus</subject><subject>Leukocytes</subject><subject>Probiotics</subject><subject>Supplements</subject><subject>Xenografts</subject><subject>Xenotransplantation</subject><issn>0163-5581</issn><issn>1532-7914</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc9uFSEUh4mxsdfqI2hI3LiZlr8Ds7O9qdcmt9HEdk0YBizNDIzAtOkz-NJyc29duOiKE_KdH-fwAfABo1OMJDpDuKWcS3xKEKlXkhJCxSuwwpySRnSYvQarHdPsoGPwNud7hJDAVL4Bx5R2nItOrMCfHyn2PhZv4FabEntt_DguGaY7PYWYa_VzmefRTjYUXXwM8GqaU3ywA1zr2RpfdO-DhTWnWFP8g4WXztUK6l_ah1zgRueSav5aB2MT3KT4WO6gD_BajxZenG8vzgy89sa-A0dOj9m-P5wn4Pbr5c36W7P9vrlan28bQ1FXGqMlctzV8QcsHGPEYisxd1y6gVGORG84buXg2r4bhGCMDkiYjjlBHJKtpCfg8z637vF7sbmoyWdjx1EHG5esCCekxS2TuKKf_kPv45JCna5SErecMtpWiu8pk2LOyTo1Jz_p9KQwUjtb6tmW2tlSB1u17-MhfeknO_zretZTgS97wAcX06QfYxoHVfTTGJNL9T99VvTlN_4CKvSkMA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Rahimi, Ahmad Mustafa</creator><creator>Nabavizadeh, Fatemeh</creator><creator>Ashabi, Ghorbangol</creator><creator>Halimi, Shahnaz</creator><creator>Rahimpour, Milad</creator><creator>Vahedian, Jalal</creator><creator>Panahi, Mahshid</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>2021</creationdate><title>Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice</title><author>Rahimi, Ahmad Mustafa ; Nabavizadeh, Fatemeh ; Ashabi, Ghorbangol ; Halimi, Shahnaz ; Rahimpour, Milad ; Vahedian, Jalal ; Panahi, Mahshid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Blood</topic><topic>Cancer</topic><topic>Carcinogenesis</topic><topic>Carcinogens</topic><topic>Cyclosporins</topic><topic>Dietary supplements</topic><topic>Erythrocytes</topic><topic>Gastric cancer</topic><topic>Graft rejection</topic><topic>Grafting</topic><topic>Lactobacilli</topic><topic>Lactobacillus rhamnosus</topic><topic>Leukocytes</topic><topic>Probiotics</topic><topic>Supplements</topic><topic>Xenografts</topic><topic>Xenotransplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahimi, Ahmad Mustafa</creatorcontrib><creatorcontrib>Nabavizadeh, Fatemeh</creatorcontrib><creatorcontrib>Ashabi, Ghorbangol</creatorcontrib><creatorcontrib>Halimi, Shahnaz</creatorcontrib><creatorcontrib>Rahimpour, Milad</creatorcontrib><creatorcontrib>Vahedian, Jalal</creatorcontrib><creatorcontrib>Panahi, Mahshid</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition and cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahimi, Ahmad Mustafa</au><au>Nabavizadeh, Fatemeh</au><au>Ashabi, Ghorbangol</au><au>Halimi, Shahnaz</au><au>Rahimpour, Milad</au><au>Vahedian, Jalal</au><au>Panahi, Mahshid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice</atitle><jtitle>Nutrition and cancer</jtitle><addtitle>Nutr Cancer</addtitle><date>2021</date><risdate>2021</risdate><volume>73</volume><issue>10</issue><spage>2089</spage><epage>2099</epage><pages>2089-2099</pages><issn>0163-5581</issn><eissn>1532-7914</eissn><abstract>The gastric cancer (GC) is biologically and genetically heterogeneous with a poorly understood carcinogenesis at the molecular level. Herein, we studied the effects of probiotics (Lactobacillus rhamnosus) on subcutaneous implantation of xenograft GC. Moreover, the effect of probiotics (L. rhamnosus) was compared with the capecitabine drug as known used drug against GC. Human GC tissue was obtained from patients with gastric adenocarcinoma and grafted into mice armpit. Probiotic (L. rhamnosus) was given to animals by gavage 2 weeks prior to GC and 4 weeks after GC induction. Also, capecitabine was orally added through feeding tube at the last week of treatment procedure. All grafted animals received cyclosporine a day before the surgery and during the study period to prevent graft rejection. Capecitabine-probiotic complex reduced the size of the axillary implanted GC when compared with control group. Furthermore, combination of capecitabine and probiotic increased apoptotic and necrotic responses in the grafted tumor, blood cells (red blood cells, white blood cells, and platelet counts) in comparison with capecitabine. Probiotic (L. rhamnosus) administration effectively improved the therapeutic index and outcomes, and also, improved the therapeutic effects of the capecitabine.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>33955797</pmid><doi>10.1080/01635581.2020.1832237</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-5581 |
ispartof | Nutrition and cancer, 2021, Vol.73 (10), p.2089-2099 |
issn | 0163-5581 1532-7914 |
language | eng |
recordid | cdi_proquest_journals_2581653436 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Adenocarcinoma Animals Apoptosis Blood Cancer Carcinogenesis Carcinogens Cyclosporins Dietary supplements Erythrocytes Gastric cancer Graft rejection Grafting Lactobacilli Lactobacillus rhamnosus Leukocytes Probiotics Supplements Xenografts Xenotransplantation |
title | Probiotic Lactobacillus rhamnosus Supplementation Improved Capecitabine Protective Effect against Gastric Cancer Growth in Male BALB/c Mice |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T11%3A27%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotic%20Lactobacillus%20rhamnosus%20Supplementation%20Improved%20Capecitabine%20Protective%20Effect%20against%20Gastric%20Cancer%20Growth%20in%20Male%20BALB/c%20Mice&rft.jtitle=Nutrition%20and%20cancer&rft.au=Rahimi,%20Ahmad%20Mustafa&rft.date=2021&rft.volume=73&rft.issue=10&rft.spage=2089&rft.epage=2099&rft.pages=2089-2099&rft.issn=0163-5581&rft.eissn=1532-7914&rft_id=info:doi/10.1080/01635581.2020.1832237&rft_dat=%3Cproquest_infor%3E2581653436%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c309t-ca80f5f797d17f442e1e815f58fd43507bc5168df6b9d77443d07c94f72f08683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2581653436&rft_id=info:pmid/33955797&rfr_iscdi=true |